Novo Nordisk A/S Company Profile (NYSE:NVO)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVO
  • CUSIP:
Key Metrics:
  • Previous Close: $44.43
  • 50 Day Moving Average: $46.54
  • 200 Day Moving Average: $52.89
  • 52-Week Range: $44.04 - $59.00
  • Trailing P/E Ratio: 21.03
  • Foreward P/E Ratio: 18.21
  • P/E Growth: 1.82
  • Market Cap: $112.69B
  • Outstanding Shares: 2,536,300,000
  • Beta: 0.74
Profitability:
  • Net Margins: 32.71%
  • Return on Equity: 84.61%
  • Return on Assets: 41.36%
Debt:
  • Current Ratio: 1.27%
  • Quick Ratio: 0.94%
Additional Links:
Companies Related to Novo Nordisk A/S:

Analyst Ratings

Consensus Ratings for Novo Nordisk A/S (NYSE:NVO) (?)
Ratings Breakdown: 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $57.00 (28.29% upside)

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Piper Jaffray Cos.Initiated CoverageNeutralView Rating Details
9/17/2016Bank of America Corp.Set Price TargetHold$57.00View Rating Details
9/14/2016Jefferies GroupReiterated RatingHoldView Rating Details
9/13/2016BNP ParibasUpgradeNeutral -> OutperformView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformView Rating Details
9/12/2016Deutsche Bank AGUpgradeHold -> BuyView Rating Details
9/9/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
9/1/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
8/31/2016HSBCUpgradeReduce -> HoldView Rating Details
8/3/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
6/28/2016Goldman Sachs Group Inc.DowngradeConviction-Buy -> BuyView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyView Rating Details
9/21/2015SwedbankUpgradeStrong-BuyView Rating Details
8/28/2015Leerink SwannInitiated CoverageMarket Perform$56.00View Rating Details
8/10/2015Main First Bank AGDowngradeHoldView Rating Details
4/15/2015Societe GeneraleInitiated CoverageSellView Rating Details
3/26/2015Bryan, Garnier & CoDowngradeNeutralView Rating Details
1/29/2015Commerzbank AGDowngradeHoldView Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Novo Nordisk A/S (NYSE:NVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2016Q1$0.53$0.57ViewListenView Earnings Details
10/29/2015Q3$0.47$0.48ViewN/AView Earnings Details
8/6/2015Q215$3.31$3.23$3.98 billion$27.06 billionViewN/AView Earnings Details
4/30/2015Q1$3.20$3.02$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
10/30/2014Q3$2.45$2.47$22.25 billion$22.25 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$2.37$2.43$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
Current Year EPS Consensus Estimate: $2.30 EPS
Next Year EPS Consensus Estimate: $2.44 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.53$0.48
Q2 20162$0.57$0.58$0.58
Q3 20161$0.54$0.54$0.54
Q4 20161$0.52$0.52$0.52
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
Annual Dividend:$1.03
Dividend Yield:2.32%
Dividend Growth:13.30% (3 Year Average)
Payout Ratio:48.82% (Based on Trailing 12 Months of Earnings)
44.78% (Based on Current Year Consensus EPS Estimate)
42.21% (Based on Next Year Consensus EPS Estimate)
Track Record:19 Years of Consecutive Dividend Growth

Dividend History for Novo Nordisk A/S (NYSE:NVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/8/2016$0.338/11/20168/15/20168/23/2016
2/16/2016Annual$0.703/18/20163/22/20163/30/2016
3/17/2014annual$0.841.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.181.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership Percentage: 7.54%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
DateHeadline
publicnow.com logoNovo Nordisk A/S - Share repurchase programme (NYSE:NVO)
www.publicnow.com - September 26 at 11:10 AM
News IconDrug Manufacturers – Other: Novo Nordisk A/S (NYSE:NVO) Position of the day (NYSE:NVO)
twincountynews.com - September 23 at 6:03 PM
investornewswire.com logoNovo Nordisk A/S (NYSE:NVO) EPS Projection At $0.52 - Investor Newswire (NYSE:NVO)
www.investornewswire.com - September 23 at 11:13 AM
publicnow.com logoNovo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label (NYSE:NVO)
www.publicnow.com - September 23 at 11:13 AM
News IconNovo Nordisk A/S (NYSE:NVO) from Drug Manufacturers – Other – Todays Top Gains (NYSE:NVO)
twincountynews.com - September 22 at 11:20 AM
News IconHC Stocks Indications! Teva Pharmaceutical Industries Ltd (ADR ... - share market updates (press release) (NYSE:NVO)
sharemarketupdates.com - September 21 at 6:08 PM
News IconNovo Nordisk (ADR)(NYSE:NVO) Heffx Trading Outlook - Live Trading News (NYSE:NVO)
www.livetradingnews.com - September 21 at 6:08 PM
News IconTracking This Dividend Stock With Upside Possibility: Novo Nordisk A/S (NYSE:NVO) - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 21 at 6:08 PM
News IconStock in Limelight: Novo Nordisk A/S (NYSE:NVO), United Technologies Corporation (NYSE:UTX) - Newburgh Press (NYSE:NVO)
newburghpress.com - September 21 at 6:08 PM
finance.yahoo.com logoNovo Nordisk to supply insulin at discount to poorest nations (NYSE:NVO)
finance.yahoo.com - September 21 at 6:08 PM
News IconLeading stocks in today’s market: Novo Nordisk A/S (NYSE:NVO) (NYSE:NVO)
twincountynews.com - September 21 at 10:37 AM
News IconHigh Market Cap Stock of the Day – Novo Nordisk A/S (NYSE:NVO) (NYSE:NVO)
twincountynews.com - September 20 at 11:46 AM
News IconStocks With Perfect Match- International Business Machines (NYSE:IBM), Novo Nordisk (NYSE:NVO) - Seneca Globe (NYSE:NVO)
www.senecaglobe.com - September 19 at 6:29 PM
News IconAdobe Systems Incorporated (NASDAQ:ADBE) & Novo Nordisk A/S (ADR) (NYSE:NVO) UPDATE ON U.S STOCKS ... - Money News (NYSE:NVO)
www.newsismoney.com - September 17 at 10:57 AM
streetinsider.com logoNovo Nordisk (NVO) Receives positive CHMP Opinion for NovoRapid Marketing Adjustment - StreetInsider.com (NYSE:NVO)
www.streetinsider.com - September 17 at 10:57 AM
streetinsider.com logoNovo Nordisk (NVO) Receives positive CHMP Opinion for NovoRapid Marketing Adjustment (NYSE:NVO)
www.streetinsider.com - September 16 at 6:19 PM
News IconIs Novo Nordisk A/S (NYSE:NVO), a large market cap stock a smart buy? (NYSE:NVO)
twincountynews.com - September 16 at 6:19 PM
News IconNovo Nordisk A/S (NVO) Upgraded to "Buy" at Deutsche Bank AG (NYSE:NVO)
magseriesusa.net - September 16 at 10:00 AM
publicnow.com logoNovoRapid® receives positive CHMP opinion for extended use in children as young as one year old (NYSE:NVO)
www.publicnow.com - September 16 at 10:00 AM
publicnow.com logoVictoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk (NYSE:NVO)
www.publicnow.com - September 15 at 6:33 PM
finance.yahoo.com logoGreat Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women (NYSE:NVO)
finance.yahoo.com - September 15 at 6:33 PM
News IconNovo Nordisk A/S's (NVO): Hot Watch to Target - Hot Stocks Point (NYSE:NVO)
www.hotstockspoint.com - September 15 at 9:57 AM
prnewswire.com logoDrug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences - PR Newswire (press release) (NYSE:NVO)
www.prnewswire.com - September 15 at 9:57 AM
marketrealist.com logoHow Sanofi’s Various Franchises Performed in 2Q16 (NYSE:NVO)
marketrealist.com - September 14 at 6:36 PM
News IconNovo Nordisk A/S (NVO) Downgraded to "Neutral" at JPMorgan Chase & Co (NYSE:NVO)
www.crcconnection.com - September 14 at 10:46 AM
publicnow.com logoAdults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with... (NYSE:NVO)
www.publicnow.com - September 14 at 10:46 AM
publicnow.com logoSaxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment (NYSE:NVO)
www.publicnow.com - September 14 at 10:46 AM
News IconTracking This Dividend Stock With Possible Upside Potential: Novo Nordisk A/S (NYSE:NVO) - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 12 at 6:13 PM
capitalcube.com logoETF’s with exposure to Novo Nordisk A/S : September 12, 2016 (NYSE:NVO)
www.capitalcube.com - September 12 at 6:13 PM
thestreet.com logoNovo Nordisk (NVO) Stock Advances, Deutsche Bank Upgrades (NYSE:NVO)
www.thestreet.com - September 12 at 6:13 PM
benzinga.com logoBarron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More - Benzinga (NYSE:NVO)
www.benzinga.com - September 11 at 5:53 PM
finance.yahoo.com logoBarron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More (NYSE:NVO)
finance.yahoo.com - September 11 at 5:53 PM
News IconSelling Boundary Nears To- Medivation (NASDAQ:MDVN), Novo Nordisk A/S (NYSE:NVO) - Seneca Globe (NYSE:NVO)
www.senecaglobe.com - September 10 at 5:50 PM
finance.yahoo.com logoNOVO NORDISK A S Financials (NYSE:NVO)
finance.yahoo.com - September 10 at 5:50 PM
barrons.com logo[$$] Denmark's Novo Nordisk Plots a Recovery (NYSE:NVO)
www.barrons.com - September 10 at 10:46 AM
marketexclusive.com logoInside The FDA: Eli Lilly and Co (NYSE:LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree? (NYSE:NVO)
marketexclusive.com - September 9 at 11:09 AM
finance.yahoo.com logoPharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib (NYSE:NVO)
finance.yahoo.com - September 9 at 11:09 AM
News IconPlacing Novo Nordisk A/S (NYSE:NVO) Shares Under the Microscope - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 7 at 10:04 AM
News IconStocks with Active Concerns- Novo Nordisk A/S (NVO), Communications Sales & Leasing (NASDAQ:CSAL ... - Seneca Globe (NYSE:NVO)
www.senecaglobe.com - September 5 at 10:42 AM
News IconAnalysis on Dividend Stock With Possible Future Upside: Novo Nordisk A/S (NYSE:NVO) - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 2 at 6:27 PM
ft.com logo[$$] Lars Fruergaard Jorgensen a model for 'Novo Nordisk Way' (NYSE:NVO)
www.ft.com - September 2 at 6:27 PM
finance.yahoo.com logo5:49 pm Novo Nordisk A/S announces that the FDA extended regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes (NYSE:NVO)
finance.yahoo.com - September 2 at 6:27 PM
News IconLong Term Growth Shares in Review: Novo Nordisk A/S (NYSE:NVO) - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 2 at 11:21 AM
News IconStock Gapping Down Pre-Bell: Novo Nordisk A/S (NYSE:NVO) - Post News (NYSE:NVO)
www.kentuckypostnews.com - September 2 at 11:21 AM
bloomberg.com logoNovo Taps Veteran as CEO to Tackle Unprecedented Competition (NYSE:NVO)
www.bloomberg.com - September 1 at 6:28 PM
thestreet.com logoNovo Nordisk (NVO) Stock Falls, CEO Rebien Sorensen Retires (NYSE:NVO)
www.thestreet.com - September 1 at 6:28 PM
finance.yahoo.com logoNovo Nordisk A/S downgraded by Morgan Stanley (NYSE:NVO)
finance.yahoo.com - September 1 at 6:28 PM
ft.com logo[$$] Novo Nordisk chief executive retires in shake-up (NYSE:NVO)
www.ft.com - September 1 at 6:28 PM
ft.com logo[$$] Novo Nordisk: long Lars-ting (NYSE:NVO)
www.ft.com - September 1 at 6:28 PM
News IconLars Rebien Sørensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jørgensen appointed as successor (NYSE:NVO)
www.bioportfolio.com - September 1 at 9:41 AM

Social

Novo Nordisk A/S (NYSE:NVO) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff